Sutro Biopharma (STRO) Competitors

Sutro Biopharma (NASDAQ:STRO) and Olema Pharmaceuticals (NASDAQ:OLMA) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment.

Which has higher earnings and valuation, STRO or OLMA?

Olema Pharmaceuticals has lower revenue, but higher earnings than Sutro Biopharma. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Sutro Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sutro Biopharma	$66.43M	1.05	-$106.79M	-$2.98	-0.28
Olema Pharmaceuticals	N/A	N/A	-$96.65M	-$2.01	-2.03

Does the MarketBeat Community prefer STRO or OLMA?

Sutro Biopharma received 93 more outperform votes than Olema Pharmaceuticals when rated by MarketBeat users. However, 72.22% of users gave Olema Pharmaceuticals an outperform vote while only 63.46% of users gave Sutro Biopharma an outperform vote.

Company	Underperform	Outperform
Sutro Biopharma	Outperform Votes 132 63.46%	Underperform Votes 76 36.54%
Olema Pharmaceuticals	Outperform Votes 39 72.22%	Underperform Votes 15 27.78%

Do analysts recommend STRO or OLMA?

Sutro Biopharma presently has a consensus price target of $6.11, indicating a potential upside of 639.51%. Olema Pharmaceuticals has a consensus price target of $24.50, indicating a potential upside of 500.49%. Given Sutro Biopharma's higher probable upside, analysts clearly believe Sutro Biopharma is more favorable than Olema Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sutro Biopharma	1 Sell rating(s)	5 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.13
Olema Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more risk and volatility, STRO or OLMA?

Sutro Biopharma has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500. Comparatively, Olema Pharmaceuticals has a beta of 1.99, meaning that its stock price is 99% more volatile than the S&P 500.

Do institutionals & insiders have more ownership in STRO or OLMA?

97.0% of Sutro Biopharma shares are owned by institutional investors. Comparatively, 91.8% of Olema Pharmaceuticals shares are owned by institutional investors. 3.6% of Sutro Biopharma shares are owned by insiders. Comparatively, 16.4% of Olema Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Is STRO or OLMA more profitable?

Olema Pharmaceuticals has a net margin of 0.00% compared to Sutro Biopharma's net margin of -77.01%. Olema Pharmaceuticals' return on equity of -53.56% beat Sutro Biopharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sutro Biopharma	-77.01%	-101.89%	-28.69%
Olema Pharmaceuticals	N/A	-53.56%	-47.86%

Does the media refer more to STRO or OLMA?

In the previous week, Olema Pharmaceuticals had 1 more articles in the media than Sutro Biopharma. MarketBeat recorded 3 mentions for Olema Pharmaceuticals and 2 mentions for Sutro Biopharma. Sutro Biopharma's average media sentiment score of 1.78 beat Olema Pharmaceuticals' score of -0.03 indicating that Sutro Biopharma is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sutro Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Olema Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Olema Pharmaceuticals beats Sutro Biopharma on 10 of the 17 factors compared between the two stocks.